Let’s face it: We all love to compare ourselves with others, especially if it makes us look good. However, when it comes to investing, comparing your portfolio with a benchmark and trying to beat the market focuses the attention on relative success rather than a definitive long-term goal. And since the market is an amorphous thing that you have no control over, using it to evaluate your portfolio can be perilous.
See Also: Great Funds for Income in Retirement
Consider Garrison Keillor, host of radio show “A Prairie Home Companion,” describing Lake Wobegon as “a place where the women are strong, all the men are good looking and all the children are above average.” Of course, the simple assertion that all the children are above average ties into our hope and desires for our children and so on. Yet we all know that the average is made up of everyone, and someone has to be below average.
Top 10 Electric Utility Stocks To Watch For 2017: Nu Skin Enterprises Inc.(NUS)
Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements worldwide. The company sells its personal care products under the Nu Skin brand; and nutritional supplements under the Pharmanex brand. Its personal care product line includes core systems, targeted treatments, total care, cosmetic, and Epoch, a product formulated with botanical ingredients. The company?s nutritional supplements product line comprises micronutrient supplements, targeted solution supplements, and weight management products. It also sells Vitameal, which are nutritious meal products for starving children or purchased for personal food storage. In addition, the company offers other products and services consisting of digital content storage, water purifiers, and other household products. It sells its products primarily through a network of independent distributors in north Asia, the Americas, Greater China, Europe, and the south Asia/Pacific. The c ompany also operates retail stores to sell its products in China. As of December 31, 2010, Nu Skin Enterprises operated 40 stores throughout China. The company was founded in 1984 and is headquartered in Provo, Utah.
- [By Scott Rubin]
Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
Top 10 Electric Utility Stocks To Watch For 2017: Bank Of Montreal(BMO)
Bank of Montreal provides diversified financial services primarily in North America. The companys personal banking products and services include chequing and savings accounts, credit cards, mortgages, creditor insurance, and financial and investment advice; and commercial banking products and services comprise business deposit accounts, commercial credit cards, business loans and commercial mortgages, cash management solutions, foreign exchange, and specialized banking programs for small business and commercial banking customers. It also offers wealth management products and services, such as investment and wealth advisory services; online investing services; financial services and solutions to high net worth and ultra-high net worth clients; and investment management, and trust and custody services to institutional, retail, and high net worth investors. In addition, the company provides life insurance, accident and sickness insurance, and annuity products to brokers and individuals, as well as reinsurance solutions. Further, it offers investment and corporate banking services, including clients debt and equity capital-raising services, as well as loan origination and syndication, balance sheet management solutions, and treasury management services; strategic advice on mergers and acquisitions, restructurings, and recapitalizations, as well as valuation and fairness opinions; and trade finance, risk mitigation, and other operating services. Additionally, the company provides trading products comprising research and access to global markets for institutional, corporate, and retail clients; new product development and origination services, as well as risk management advice and services to hedge against fluctuations; and funding and liquidity management services to its clients. It operates approximately 1,500 bank branches. Bank of Montreal was founded in 1817 and is headquartered in Montreal, C anada.
- [By Monica Gerson]
Bank of Montreal (USA) (NYSE: BMO) is expected to report its quarterly earnings at $1.76 per share on revenue of $5.02 billion.
EVINE Live Inc (NASDAQ: EVLV) is projected to report a quarterly loss at $0.10 per share on revenue of $162.13 million.
Hot Stocks To Watch For 2017: Progenics Pharmaceuticals Inc.(PGNX)
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Azedra is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands. The Company has completed enrollment in pivotal Phase IIb clinical trial under Special Protocol Assessment (SPA).
The Company’s 1404 (trofolastat) is a technetium-99m labeled small molecule, which binds prostate specific membrane antigen (PSMA) and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. The Company has completed a global multi-centered Phase II study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and initiated a multi-center, open-label Phase III trial to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients hav e clinically prostate cancer
PyL ((18F) DCFPyL)!
The Company’s PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. The Company’s studies show the uptake of PyL is high in sites of putative metastatic lesions and primary tumors, suggesting the potential for high sensitivity in detecting prostate cancer.
The Company’s 1095 is a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule, which is designed to deliver a dose of radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The Company focuses on initiating a Phase I clinical study.
PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer. The Company’s Phase II, multicenter clinical tr ial to assess the safety, tolerability and anti-tumor activity of PSMA ADC, has been completed in both the chemotherapy refractory and chemotherapy naive patients with metastatic castration-resistant prostate cancer (mCRPC).
The Company’s Relistor is used as a treatment for Opioid-Induced Constipation (OIC), which decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor-Subcutaneous injection is engaged in the treatment of OIC in patients with non-cancer pain, and is marketed in the United States. Relistor-Oral has completed Phase III clinical trials.
The Company’s PRO 140 is a humanized IgG4 monoclonal antibody directed against C-C chemokine receptor type 5 (CCR5), a molecular portal that human immunodeficiency virus (HIV) uses to enter T-cells. PRO 140 blocks the predominant HIV subtype (R5) entry i nto T-cells by masking this required co-receptor, CCR5. PRO ! 140 has b! een the subject of over seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.
The Company competes with Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Shionogi & Co., Theravance, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc. and Aytu Bioscience Inc.
- [By Ben Levisohn]
After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).
- [By Lisa Levin]
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Top 10 Electric Utility Stocks To Watch For 2017: Cooper Tire & Rubber Company(CTB)
Cooper Tire & Rubber Company (Cooper), incorporated on March 26, 1930, is a manufacturer and marketer of replacement tires. The Company specializes in the design, manufacture, marketing and sales of passenger car and light truck tires. Cooper and its subsidiaries also sell medium truck, motorcycle and racing tires. The Company is organized into four business segments: North America, composed of the Company’s operations in the United States and Canada; Latin America, composed of the Company’s operations in Mexico, Central America and South America; Europe, and Asia. The North America and Latin America segments are similar in their production and distribution processes, and are presented as the Americas Tire Operations segment. The results of the combined Asia and Europe segments are presented as International Tire Operations segment. Cooper and its family of companies operate approximately eight manufacturing facilities and over 20 distribution centers in over 10 countries.
Americas Tire Operations segment
The Company’s Americas Tire Operations segment manufactures and markets passenger car and light truck tires, primarily for sale in the United States replacement market. The segment also has a joint venture manufacturing operation in Mexico with Corporacion de Occidente SA de CV (COOCSA), which supplies passenger car tires to the United States, Mexican, Central American and South American markets. The segment also distributes tires for racing, medium truck and motorcycles. The racing and motorcycle tires are manufactured in the Company’s European Operations and by others. The medium truck tires are sourced through an off-take agreement with the Company’s joint venture, which is known as Prinx Chengshan (Shandong) Tire Company Ltd. Its distribution channels and customers include independent tire dealers, wholesale distributors, regional and national retail tire chains, and retail chains that sell tires, as well as oth er automotive products. The segment sells a limited number o! f tires to original equipment manufacturers (OEMS). The segment’s replacement tire business has a customer base that includes purchasers of brand tires that are marketed and distributed by the Company and private label tires which are manufactured by the Company but marketed and distributed by the Company’s customers. The segment is a supplier of private label tires in the United States.
International Tire Operations segment
The Company’s International Tire Operations segment is the combination of the Asia and Europe operating segments. The European operations have manufacturing operations in the United Kingdom and the Republic of Serbia (Serbia). The United Kingdom entity manufactures and markets passenger car, light truck, motorcycle and racing tires and tire retread material for the domestic and global markets. The Serbian entity manufactures light vehicle tires for the European markets and for export to the United States. The Asian operations ar e located in the People’s Republic of China (PRC). In the PRC, Cooper Kunshan Tire manufactures light vehicle tires and, under an agreement with the government of the PRC, these tires were exported to markets outside of the PRC. The majority of the tires manufactured by the International Tire Operations segment are sold in the replacement market. The segment has also sales, marketing, distribution and research and development capabilities.
The Company competes with Bridgestone Corporation, Goodyear Tire & Rubber Company and Groupe Michelin.
- [By Chad Fraser]
Goodyear shares have risen sharply so far in 2013, including significant jumps in the wake of the latest earnings report and on news of rival Cooper Tire & Rubber Co. (NYSE: CTB) being taken over by India’s Apollo Tyres.
Top 10 Electric Utility Stocks To Watch For 2017: Blackrock Global(BOE)
BlackRock Global Opportunities Equity Trust (the Trust), incorporated on February 22, 2005, is an investment trust. The Trusts primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions.
Under normal circumstances, the Trust invests its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives. BlackRock Advisors, LLC is an investment advisor of the Trust. The Trust invests in various sectors, such as energy, consumer p roducts, financial institutions, industrials, technology, basic materials, telecommunications, health care, real estate, transportation, aerospace and defense, automotive, building and development, and entertainment and leisure.
- [By Robert Rapier]
Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.
Top 10 Electric Utility Stocks To Watch For 2017: Smith & Nephew SNATS, Inc.(SNN)
Smith & Nephew plc develops, manufactures, markets, and sells medical technology products and services worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; gynecological instrumentation devices; knee implant products for specialized knee replac ement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat. In addition, the company offers advanced wound care products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound devices, including traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
- [By Charles Carlson, CEO and Portfolio Manager, Horizon Investment Services]
For investors looking for growth but also income, I especially like three health-care related stocksFresenius Medical (FMS), Novo Nordisk (NVO), and Smith & Nephew (SNN).
Top 10 Electric Utility Stocks To Watch For 2017: Transocean Inc.(RIG)
Transocean Ltd. provides offshore contract drilling services for oil and gas wells worldwide. It offers deepwater and harsh environment drilling, oil and gas drilling management, and drilling engineering and drilling project management services. The company also offers well and logistics services. In addition, it engages in oil and gas exploration, development, and production activities primarily in the United States offshore Louisiana and Texas, and in the United Kingdom sector of the North Sea. As of February 10, 2011, the company owned, had partial ownership interests in, and operated 138 mobile offshore drilling units, including 47 high-specification floaters, 25 midwater floaters, 9 high-specification jackups, 54 standard jackups, and 3 other rigs, as well as 1 ultra-deepwater floater and 3 high-specification jackups under construction. Transocean Ltd. was founded in 1953 and is based in Zug, Switzerland.
- [By Ben Levisohn]
Shares of Noble have gained 5% to $9.32 at 1:59, but that appears downright disappointing next to Seadrill (SDRL), Transocean (RIG) and Atwood Oceanics (ATW). Transocean has climbed 7.2% to $11.28, Seadrill has jumped 7.6% to $3.40, and Atwood Oceanics has soared 9.9% to $12.31.
Top 10 Electric Utility Stocks To Watch For 2017: 8point3 Energy Partners LP(CAFD)
8point3 Energy Partners LP (8point3 Partners) is a limited partnership formed by First Solar and SunPower to own, operate and acquire solar energy generation projects. The Company’s portfolio includes utility projects, and commercial and industrial (C&I) projects.
The Company’s utility projects include Maryland Solar, Solar Gen 2, Lost Hills / Blackwell, North Star, RPU and Quinto. The Company owns 100% of Maryland Solar project, which is located in Maryland. The Maryland Solar project entity owns the 20 megawatt Maryland Solar project. 8point3 Partners owns 49% of the Solar Gen 2 project, which is located in California. The Solar Gen 2 project entity owns the 150 megawatt Solar Gen 2 project. The Company owns 49% of the Lost Hills / Blackwell project. The Lost Hills Project entity owns the 20 megawatt Lost Hills Project and the Blackwell Project entity owns the 12 megawatt Blackwell Project, which are located on adjoining sites in Kern County, California. The Company owns 49% of the North Star project, which is located in California. The North Star project Entity owns the 60 megawatt North Star project. The Company owns 100% of RPU project, which consist of approximately seven megawatt solar generation facility located in Riverside County, California. The Company owns 100% of Quinto project, which consists of 108 megawatt solar generation facility located in Merced County, California.
The Company’s C&I projects include UC Davis project and Macy’s project. The Company owns 100% of UC Davis project, which consists of 13 megawatt solar generation facility located in Solano County, California. The Company owns 100% of Macy’s project, which consists of seven solar generation facilities with a total of approximately three megawatts located in Sacramento, Santa Clara, Santa Cruz, Alameda, and San Francisco Counties, California.
The Company’s residential portfolio consists of residential solar energy systems wi th an aggregate of 39 megawatts of capacity and an average s! olar energy system capacity of approximately 7.95 kilowatts. The Company’s residential portfolio consists of approximately 5,900 solar installations located in Arizona, California, Colorado, Hawaii, Massachusetts, New Jersey, New York, Pennsylvania and Vermont.
- [By Monica Gerson]
General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion. Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million. Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million. Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion. Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million. Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million. UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million. Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million. OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million. 8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million. Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million. Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million. Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million. Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter. Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share. Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea
Top 10 Electric Utility Stocks To Watch For 2017: Paychex Inc.(PAYX)
Paychex Inc., together with its subsidiaries, provides payroll, human resource, and benefits outsourcing solutions for small-to medium-sized businesses in the United States and Germany. It offers payroll processing services, including calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and management reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients? payroll obligations. The company also provides payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. Its human resource outsourcing services include payroll, employer compliance, human resource and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained human resource representative, as well as provides employee handbooks, management manuals, and r equired regulatory forms. In addition, the company offers retirement services administration; workers? compensation; business-owner policies; commercial auto; and health and benefits coverage, including health, dental, vision, and life. Further, it provides online human resource administration software products for employee benefits management and administration, and time and attendance solutions. As of May 31, 2010, the company served approximately 536,000 clients in the United States; and 1,700 clients in Germany. Paychex, Inc. was founded in 1971 and is headquartered in Rochester, New York.
- [By Monica Gerson]
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Paychex, Inc. (NASDAQ: PAYX) is estimated to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Paychex shares rose 1.10 percent to close at $56.14 on Wednesday. Wall Street expects Micron Technology, Inc. (NASDAQ: MU) to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. Micron shares rose 0.76 percent to $13.29 in after-hours trading. Pier 1 Imports Inc (NYSE: PIR) reported a wider-than-expected loss for its first quarter and issued a weak outlook. Pier 1 Imports shares dropped 6.07 percent to $5.11 in the after-hours trading session. Analysts are expecting McCormick & Company, Incorporated (NYSE: MKC) to have earned $0.74 per share on revenue of $1.06 billion in the latest quarter. McCormick shares fell 0.59 percent to $102.10 in after-hours trading.
Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas
- [By Monica Gerson]
Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion. ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion. Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion. Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share. Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million. Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million. Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
- [By Monica Gerson]
Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.50 per share on revenue of $751.20 million.
UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.26 per share on revenue of $362.62 million.
Top 10 Electric Utility Stocks To Watch For 2017: Sanofi(SNY)
Sanofi, formerly Sanofi-Aventis, incorporated on May 11, 1994, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company has three operating segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from its subsidiary, Genzyme Corporation. Its pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Pharmaceuticals segment also includes associates with activities related to pharmaceuticals. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Vaccines segment includes the Sanofi Pasteur MSD joint venture. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a r ange of medicines and vaccines for a range of animal species. The Company’s Animal Health segment includes its subsidiaries, Merial, Inc. and Merial S.A.S. It also operates in the Other segment, which includes the effects of retained commitments in respect of divested activities.
The Company’s Pharmaceuticals segment includes marketed products grouped into the fields of diabetes, cardiovascular disease, rare diseases, multiple sclerosis (MS) and oncology. It also has a presence in consumer healthcare and generics. Its principal diabetes products are Lantus and Toujeo, which are long acting analogs of human insulin; Amaryl, which is a sulfonylurea; Apidra, which is a rapid acting analog of human insulin; Insuman, which is a human insulin, and Lyxumia (lixisenatide), which is a once-daily prandial glucagon-like peptide (GLP)-1 receptor agonist. Its cardiovascular products include Praluent, which is a human monoclonal antibody (mAb) tha t blocks the interaction of proprotein convertase subtilisin! kexin type 9 (PSCK9) with low-density lipoprotein (LDL) receptors, and Multaq (dronedarone), which is an anti-arrhythmic drug.
The Company’s rare diseases business is focused on products for the treatment of rare genetic diseases and other chronic debilitating diseases, including lysosomal storage disorders, and offers products, such as Cerezyme, Cerdelga and Fabrazyme. Its MS franchise consists of Aubagio (teriflunomide), a once-daily oral immunomodulator, and Lemtrada (alemtuzumab), a monoclonal antibody. It has a portfolio of approximately 10 marketed products in oncology, including Jevtana, Eloxatin, Taxotere, Thymoglobulin and Zaltrap. Its prescription products and other products include Plavix/Iscover, Aprovel/ Avapro/Karvea and Renagel.
Human Vaccines (Vaccines)
The Company’s Vaccines segment offers a range of vaccines. The Company’s vaccine products consists of pediatric, combination and poliomyelitis (polio) vaccines, includin g Pentaxim and Hexaxim; influenza vaccines, including Fluzone and Intradermal (ID) trivalent influenza vaccines; adult and adolescent boosters, including Adacel and Repevax; meningitis and pneumonia vaccines, and travel and endemic vaccines, including IMOJEV.
The Company’s Animal Health segment includes Merial’s products. The Company offers a range of products for animals (both livestock and pets). These products include Frontline, which is a topical flea and tick anti-parasitic intended for dogs and cats; Heartgard, which is a parasiticide for control of heartworm in pets; Nexgard, which is an oral anti-parasitic for the treatment and prevention of fleas and ticks in dogs, and Vaxxitek, which is vector vaccine for protecting chickens against infectious bursal disease (IBD) and Marek’s disease.
The Company competes with Novo Nordisk, Boehringer Ingelheim, Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb, Nova rtis, Shire, Pfizer, Biogen Idec Inc., Teva Pharmaceuticals ! Industrie! s, Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Amgen, GlaxoSmithKline, Mylan, Actavis, Zoetis, Elanco, Virbac, Ceva and Vetoquinol.
- [By Monica Gerson]
Medivation Inc (NASDAQ: MDVN) is said to have spurned recent takeover approach from France’s Sanofi SA (ADR) (NYSE: SNY), according to sources as reported by Bloomberg on Tuesday. Sanofi wants Medivation’s treatments for hard-to-cure cancers, the sources said. Medivation shares surged 8.46 percent to $49.60 in the after-hours trading session, while Sanofi shares fell 0.59 percent to $42.02 in after-hours trading.